Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension

Jawahar L. Mehta, Larry M. Lopez, Nicholas D. Vlachakis, Alan H. Gradman, David T. Nash, Mark T. O'Connell, W. Thomas Garland, Bryant I. Pickering

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


To determine the dose-response efficacy of once-daily administration of placebo or a new long-acting calcium channel blocker amlodipine in patients with mild to moderate hypertension, a randomized, multicenter, placebo-controlled, double-blind trial was conducted. The study included 210 patients with diastolic hypertension (blood pressure 95 to 114 mm Hg) without major hematologic, renal, hepatic, cardiac, or endocrine abnormalities. After a 4-week single-blind placebo run-in period, patients were given placebo or amlodipine (1.25, 2.5, 5, or 10 mg) daily for 4 weeks. To assess the antihypertensive effect of amlodipine over a 24-hour period, blood pressure and pulse rate at weeks 0 and 4 were recorded for 12 hours after the dose and then again at 24 hours. At the end of the study patients treated with all doses of amlodipine greater than 1.25 mg daily had significantly reduced diastolic blood pressure in both supine and standing positions. Amlodipine, 1.25 mg daily, was also associated with a decrease in standing diastolic blood pressure. Response to treatment was greater in all amlodipine-treated patients than in those receiving placebo. Pulse rate in both the supine and standing positions was not significantly affected by amlodipine. At doses of 2.5, 5.0, or 10.0 mg daily, amlodipine maintained blood pressure below values obtained with placebo throughout the 24-hour period. Treatment with amlodipine was well tolerated and the incidence of side effects was low. Once-daily dosing with amlodipine is effective in the 24-hour control of blood pressure in patients with mild to moderate hypertension. Because of its efficacy as monotherapy given once a day and its low side effect profile, amlodipine may be well suited in the treatment of hypertension.

Original languageEnglish
Pages (from-to)1704-1710
Number of pages7
JournalAmerican Heart Journal
Issue number6
StatePublished - Jan 1 1993
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension'. Together they form a unique fingerprint.

Cite this